FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073482926> ?p ?o ?g. }

• W2073482926 abstract "Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DCCurrently available approaches for ovarian cancer therapy have limited success in the setting of advanced disease. Antibody-based therapeutics offer new and potentially effective strategies. Mullerian inhibiting substance (MIS, or anti-Mullerian hormone, AMH) is known for its role in embryonic development, triggering regression of the Mullerian ducts in mammalian males (in females Mullerian ducts are the source for uteri, Fallopian tubes and upper vagina). MIS signals via a heterodimeric receptor, consisting of type I (MISIR) and type II (MISIIR) receptors, where MISIIR mediates the ligand specificity and MISIR triggers the downstream signaling cascade. Approximately 64% of epithelial ovarian cancers express MISIIR with the most common expression in serous and mucinous tumors (Bakkum-Gamez et. al., Gynecol. Oncol. 2008;108(1):141). MIS has been reported to inhibit the growth of tumor xenografts in vivo (Stephen et al., Clin. Cancer Res. 2002;8(8):2640) and to trigger apoptosis of primary human ovarian cancer cells in vitro (Masaikos et al., Clin. Cancer Res. 1999;5(11):3488). This, along with the highly restricted expression pattern of MISIIR in normal tissues, suggests that MISIIR is a promising target for ovarian cancer therapy. A number of single-chain Fv molecules (scFv) and their bivalent derivatives (scFv: Fc constructs) targeting MISIIR were developed in our lab by means of screening of two large naive human scFv phage display libraries. However, to date, the potential clinical utility of these anti-MISIIR scFv molecules has been limited due to their low binding affinity.Here, we describe the screening of a third human scFv phage display library against a fusion protein representing the extracellular domain of MISIIR with the Fc domain of human IgG1 fused to its C-terminus. This screening led to selection of six unique scFv clones that specifically target MISIIR on the surface of cells with varying efficiency. One of these scFv clones, GS45, has demonstrated excellent targeting of MISIIR by flow cytometry, ELISA and surface plasmon resonance analysis. We are currently cloning GS45 into a full-length IgG molecule in order to improve its potential clinical utility.Antibodies (or antibody-based constructs, such as scFv or scFv: Fc) targeting MISIIR could be used as the basis of a variety of therapeutic strategies. They can be used on their own to induce agonistic signaling or direct antibody-dependent cell-mediated cytotoxicity (ADCC). Alternatively, MISIIR-targeting antibodies can be conjugated to cytotoxic drugs, radiolabels or imaging agents. The anti-MISIIR scFv GS45, described here, is currently being developed for ADCC and immunodrug conjugate applications. We believe it can be the basis of novel therapeutic strategies for ovarian cancer treatment.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2437." @default.
• W2073482926 created "2016-06-24" @default.
• W2073482926 creator A5002421037 @default.
• W2073482926 creator A5036175382 @default.
• W2073482926 creator A5044830720 @default.
• W2073482926 creator A5061278758 @default.
• W2073482926 creator A5070643615 @default.
• W2073482926 date "2010-04-15" @default.
• W2073482926 modified "2023-09-27" @default.
• W2073482926 title "Abstract 2437: Engineered human monoclonal antibodies targeting the Müllerian inhibiting substance type II receptor for ovarian cancer therapy" @default.
• W2073482926 doi "https://doi.org/10.1158/1538-7445.am10-2437" @default.
• W2073482926 hasPublicationYear "2010" @default.
• W2073482926 type Work @default.
• W2073482926 sameAs 2073482926 @default.
• W2073482926 citedByCount "0" @default.
• W2073482926 crossrefType "proceedings-article" @default.
• W2073482926 hasAuthorship W2073482926A5002421037 @default.
• W2073482926 hasAuthorship W2073482926A5036175382 @default.
• W2073482926 hasAuthorship W2073482926A5044830720 @default.
• W2073482926 hasAuthorship W2073482926A5061278758 @default.
• W2073482926 hasAuthorship W2073482926A5070643615 @default.
• W2073482926 hasConcept C121608353 @default.
• W2073482926 hasConcept C126322002 @default.
• W2073482926 hasConcept C150173356 @default.
• W2073482926 hasConcept C150903083 @default.
• W2073482926 hasConcept C159654299 @default.
• W2073482926 hasConcept C170493617 @default.
• W2073482926 hasConcept C203014093 @default.
• W2073482926 hasConcept C207001950 @default.
• W2073482926 hasConcept C2780427987 @default.
• W2073482926 hasConcept C502942594 @default.
• W2073482926 hasConcept C542903549 @default.
• W2073482926 hasConcept C71924100 @default.
• W2073482926 hasConcept C86803240 @default.
• W2073482926 hasConceptScore W2073482926C121608353 @default.
• W2073482926 hasConceptScore W2073482926C126322002 @default.
• W2073482926 hasConceptScore W2073482926C150173356 @default.
• W2073482926 hasConceptScore W2073482926C150903083 @default.
• W2073482926 hasConceptScore W2073482926C159654299 @default.
• W2073482926 hasConceptScore W2073482926C170493617 @default.
• W2073482926 hasConceptScore W2073482926C203014093 @default.
• W2073482926 hasConceptScore W2073482926C207001950 @default.
• W2073482926 hasConceptScore W2073482926C2780427987 @default.
• W2073482926 hasConceptScore W2073482926C502942594 @default.
• W2073482926 hasConceptScore W2073482926C542903549 @default.
• W2073482926 hasConceptScore W2073482926C71924100 @default.
• W2073482926 hasConceptScore W2073482926C86803240 @default.
• W2073482926 hasLocation W20734829261 @default.
• W2073482926 hasOpenAccess W2073482926 @default.
• W2073482926 hasPrimaryLocation W20734829261 @default.
• W2073482926 hasRelatedWork W1983608325 @default.
• W2073482926 hasRelatedWork W1991005901 @default.
• W2073482926 hasRelatedWork W2030205190 @default.
• W2073482926 hasRelatedWork W2060003702 @default.
• W2073482926 hasRelatedWork W20862047 @default.
• W2073482926 hasRelatedWork W2149153969 @default.
• W2073482926 hasRelatedWork W2165682716 @default.
• W2073482926 hasRelatedWork W2177781052 @default.
• W2073482926 hasRelatedWork W2320895053 @default.
• W2073482926 hasRelatedWork W2564362027 @default.
• W2073482926 hasRelatedWork W2573914368 @default.
• W2073482926 hasRelatedWork W2774250639 @default.
• W2073482926 hasRelatedWork W2884158964 @default.
• W2073482926 hasRelatedWork W3081485773 @default.
• W2073482926 hasRelatedWork W3088442739 @default.
• W2073482926 hasRelatedWork W3118419645 @default.
• W2073482926 hasRelatedWork W3193148543 @default.
• W2073482926 hasRelatedWork W934287052 @default.
• W2073482926 hasRelatedWork W2962237456 @default.
• W2073482926 hasRelatedWork W2964830882 @default.
• W2073482926 isParatext "false" @default.
• W2073482926 isRetracted "false" @default.
• W2073482926 magId "2073482926" @default.
• W2073482926 workType "article" @default.